News | December 13, 2025
EMA backs Eylea 8 mg for retinal vein occlusion
The positive CHMP opinion is supported by results from the Phase III QUASAR trial
The positive CHMP opinion is supported by results from the Phase III QUASAR trial
WINREVAIR is currently the first and only activin signalling inhibitor approved for PAH across all 27 EU member states
This is the first approval of a prescription transdermal dosage Form in the European markets from this facility
The patented product, developed by Venus Medicine Research Centre (VMRC) for the treatment of multidrug-resistant (MDR) infections, was sold to Cipla in 2019
The study met its primary endpoint and all 11 secondary efficacy endpoints
DUPLEX’s two-compartment, PVC- and DEHP-free design keeps medication and diluent separate until activation
MRI is particularly valuable in pediatric care due to its non-invasive nature
Senores Pharmaceuticals is poised to accelerate its presence in the Asia-Pacific region
The FDA has classified recent submissions as a major amendment pushing the approval to its NDA for TransCon CNP back three months to February 28, 2026
Surgical site infections and antimicrobial resistance remain major challenges globally
Subscribe To Our Newsletter & Stay Updated
